Cancer Drugs Fund 2.0: A Missed Opportunity? Christopher McCabeAsh PaulMike Paulden Commentary 22 March 2016 Pages: 629 - 633
Cost Implications of Value-Based Pricing for Companion Diagnostic Tests in Precision Medicine Gregory S. Zaric Current Opinion 22 February 2016 Pages: 635 - 644
Health, Health-Related Quality of Life, and Quality of Life: What is the Difference? Milad KarimiJohn Brazier Current Opinion 18 February 2016 Pages: 645 - 649
Economic Evaluation of Mental Health Interventions: A Guide to Costing Approaches James ShearerPaul McCroneRenee Romeo Practical Application 27 February 2016 Pages: 651 - 664
Discretely Integrated Condition Event (DICE) Simulation for Pharmacoeconomics J. Jaime Caro Practical Application 09 March 2016 Pages: 665 - 672
Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal Hazel SquiresMatt StevensonJohn Stevens Review Article 18 February 2016 Pages: 673 - 680
Systematic Review of Model-Based Economic Evaluations of Treatments for Alzheimer’s Disease Luis HernandezAsli OzenDenis Getsios Systematic Review 22 February 2016 Pages: 681 - 707
Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia Krithika RajagopalanDavid TruemanAntony Loebel Original Research Article Open access 11 April 2016 Pages: 709 - 721